%0 Editorial
%T Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer.
%A Moeller J
%A Green MD
%A Ramnath N
%J Transl Lung Cancer Res
%V 13
%N 6
%D 2024 Jun 30
%M 38973952
%F 4.726
%R 10.21037/tlcr-24-111